Alisol A attenuates malignant phenotypes of colorectal cancer cells by inactivating PI3K/Akt signaling

Han,Weiwei; Xing,Wenjing; Wang,Kechao; Wang,Benjun; Bai,Keyun

doi:10.3892/ol.2022.13369

Alisol A attenuates malignant phenotypes of colorectal cancer cells by inactivating PI3K/Akt signaling

Authors:
- Weiwei Han
- Wenjing Xing
- Kechao Wang
- Benjun Wang
- Keyun Bai
View Affiliations

Affiliations: Department of Anorectal, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250014, P.R. China, Department of Traditional Chinese Medicine, Zibo Central Hospital, Zibo, Shandong 255000, P.R. China
Published online on: June 7, 2022 https://doi.org/10.3892/ol.2022.13369
Article Number: 249
Copyright: © Han et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Despite the advancement in the diagnosis and therapeutic strategies for colorectal cancer, the outcomes of patients with colorectal cancer remain unsatisfactory. Alisol A is a natural constituent of Alismatis rhizoma (zexie) and has demonstrated anti‑cancer properties; however, the function of Alisol A in colorectal cancer is still unknown. In the present study, the effect of Alisol A on colorectal cancer progression was investigated. MTT and colony formation assays showed that treatment with Alisol A repressed colorectal cancer cell proliferation in a dose‑dependent manner. Similarly, western blot analysis demonstrated that Alisol A upregulated E‑cadherin protein expression levels, but downregulated N‑cadherin and Vimentin protein expression levels in colorectal cancer cells. In addition, the number of cells in G₀/G₁ phase was enhanced, while that of S phase was reduced in Alisol A‑treated colorectal cancer cells. Apoptosis and pyroptosis of colorectal cancer cells were stimulated following treatment with Alisol A. Alisol A suppressed the migration ability of colorectal cancer cells in a dose‑dependent manner. Moreover, Alisol A increased the chemotherapeutic sensitivity of colorectal cancer cells to cisplatin. Mechanically, western blot analysis confirmed that Alisol A repressed the phosphorylation levels of PI3K, Akt and mTOR in colorectal cancer cells. The Akt activator, SC79 reversed the effect of Alisol A on colorectal cancer cell proliferation and apoptosis. In conclusion, Alisol A induced an inhibitory effect on colorectal cancer progression by inactivating PI3K/Akt signaling.

View Figures

View References

1	Wrobel P and Ahmed S: Current status of immunotherapy in metastatic colorectal cancer. Int J Colorectal Dis. 34:13–25. 2019. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
3	Mármol I, Sánchez-de-Diego C, Pradilla Dieste A, Cerrada E and Rodriguez Yoldi MJ: Colorectal carcinoma: A general overview and future perspectives in colorectal cancer. Int J Mol Sci. 18:1972017. View Article : Google Scholar
4	Boland PM, Yurgelun MB and Boland CR: Recent progress in Lynch syndrome and other familial colorectal cancer syndromes. CA Cancer J Clin. 68:217–231. 2018. View Article : Google Scholar : PubMed/NCBI
5	Das S, Ciombor KK, Haraldsdottir S and Goldberg RM: Promising new agents for colorectal cancer. Curr Treat Options Oncol. 19:292018. View Article : Google Scholar
6	Yu IS and Cheung WY: Metastatic colorectal cancer in the era of personalized medicine: A more tailored approach to systemic therapy. Can J Gastroenterol Hepatol. 2018:94507542018. View Article : Google Scholar
7	Zhai Z, Yu X, Yang B, Zhang Y, Zhang L, Li X and Sun H: Colorectal cancer heterogeneity and targeted therapy: Clinical implications, challenges and solutions for treatment resistance. Semin Cell Dev Biol. 64:107–115. 2017. View Article : Google Scholar
8	Luo H, Vong CT, Chen H, Gao Y, Lyu P, Qiu L, Zhao M, Liu Q, Cheng Z, Zou J, et al: Naturally occurring anti-cancer compounds: Shining from Chinese herbal medicine. Chin Med. 14:482019. View Article : Google Scholar : PubMed/NCBI
9	Yuan H, Ma Q, Ye L and Piao G: The traditional medicine and modern medicine from natural products. Molecules. 21:5592016. View Article : Google Scholar
10	Chen DQ, Feng YL, Tian T, Chen H, Yin L, Zhao YY and Lin RC: Diuretic and anti-diuretic activities of fractions of Alismatis rhizoma. J Ethnopharmacol. 157:114–118. 2014. View Article : Google Scholar
11	Li S, Wang L, Du Z, Jin S, Song C, Jia S, Zhang Y and Jiang H: Identification of the lipid-lowering component of triterpenes from Alismatis rhizoma based on the MRM-based characteristic chemical profiles and support vector machine model. Anal Bioanal Chem. 411:3257–3268. 2019. View Article : Google Scholar : PubMed/NCBI
12	Zhang LL, Xu W, Xu YL, Chen X, Huang M and Lu JJ: Therapeutic potential of rhizoma Alismatis: A review on ethnomedicinal application, phytochemistry, pharmacology, and toxicology. Ann N Y Acad Sci. 1401:90–101. 2017. View Article : Google Scholar
13	Liu SS, Sheng WL, Li Y, Zhang SS, Zhu JJ, Gao HM, Yan LH, Wang ZM, Gao L and Zhang M: Chemical constituents from Alismatis rhizoma and their anti-inflammatory activities in vitro and in vivo. Bioorg Chem. 92:1032262019. View Article : Google Scholar : PubMed/NCBI
14	Wang K, Zhang B, Song D, Xi J, Hao W, Yuan J, Gao C, Cui Z and Cheng Z: Alisol A alleviates arterial plaque by activating AMPK/SIRT1 signaling pathway in apoE-deficient mice. Front Pharmacol. 11:5800732020. View Article : Google Scholar
15	Shi Y, Wang M, Wang P, Zhang T, Yu J, Shi L, Li M, Wang H, Zhang Q and Zhao H: Alisol A is potentially therapeutic in human breast cancer cells. Oncol Rep. 44:1266–1274. 2020. View Article : Google Scholar : PubMed/NCBI
16	Chen X, Zeng K, Xu M, Hu X, Liu X, Xu T, He B, Pan Y, Sun H and Wang S: SP1-induced lncRNA-ZFAS1 contributes to colorectal cancer progression via the miR-150-5p/VEGFA axis. Cell Death Dis. 9:9822018. View Article : Google Scholar : PubMed/NCBI
17	Haggar FA and Boushey RP: Colorectal cancer epidemiology: Incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 22:191–197. 2009. View Article : Google Scholar : PubMed/NCBI
18	Huang XM, Yang ZJ, Xie Q, Zhang ZK, Zhang H and Ma JY: Natural products for treating colorectal cancer: A mechanistic review. Biomed Pharmacother. 117:1091422019. View Article : Google Scholar : PubMed/NCBI
19	Sun X, Ng TTH, Sham KWY, Zhang L, Chan MTV, Wu WKK and Cheng CHK: Bufalin, a traditional chinese medicine compound, prevents tumor formation in two murine models of colorectal cancer. Cancer Prev Res (Phila). 12:653–666. 2019. View Article : Google Scholar : PubMed/NCBI
20	Han Q, Ma Y, Wang H, Dai Y, Chen C, Liu Y, Jing L and Sun X: Resibufogenin suppresses colorectal cancer growth and metastasis through RIP3-mediated necroptosis. J Transl Med. 16:2012018. View Article : Google Scholar : PubMed/NCBI
21	Chen Y, Wang XQ, Zhang Q, Zhu JY, Li Y, Xie CF, Li XT, Wu JS, Geng SS, Zhong CY and Han HY: (−)-Epigallocatechin-3-gallate inhibits colorectal cancer stem cells by suppressing Wnt/β-catenin pathway. Nutrients. 9:5722017. View Article : Google Scholar
22	Xiong Y, Xiong YJ, Liu DY and Shen RR: Pancratistatin inhibits the growth of colorectal cancer cells by inducing apoptosis, autophagy, and G2/M cell cycle arrest. Med Sci Monit. 25:6015–6022. 2019. View Article : Google Scholar
23	Liu W, Li W, Liu H and Yu X: Xanthohumol inhibits colorectal cancer cells via downregulation of hexokinases II-mediated glycolysis. Int J Biol Sci. 15:2497–2508. 2019. View Article : Google Scholar
24	Gamage CDB, Park SY, Yang Y, Zhou R, Taş İ, Bae WK, Kim KK, Shim JH, Kim E, Yoon G and Kim H: Deoxypodophyllotoxin exerts anti-cancer effects on colorectal cancer cells through induction of apoptosis and suppression of tumorigenesis. Int J Mol Sci. 20:26122019. View Article : Google Scholar
25	Xu W, Li X, Lin N, Zhang X, Huang X, Wu T, Tai Y, Chen S, Wu CH, Huang M and Wu S: Pharmacokinetics and tissue distribution of five major triterpenoids after oral administration of rhizoma Alismatis extract to rats using ultra high-performance liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 146:314–323. 2017. View Article : Google Scholar
26	Ho C, Gao Y, Zheng D, Liu Y, Shan S, Fang B, Zhao Y, Song D, Zhang Y and Li Q: Alisol A attenuates high-fat-diet-induced obesity and metabolic disorders via the AMPK/ACC/SREBP-1c pathway. J Cell Mol Med. 23:5108–5118. 2019. View Article : Google Scholar : PubMed/NCBI
27	Lou C, Xu X, Chen Y and Zhao H: Alisol A suppresses proliferation, migration, and invasion in human breast cancer MDA-MB-231 cells. Molecules. 24:36512019. View Article : Google Scholar
28	Chen X and Liu H: Alisol A inhibited the proliferation, migration, and invasion of nasopharyngeal carcinoma cells by inhibiting the hippo signaling pathway. Yonsei Med J. 62:895–902. 2021. View Article : Google Scholar : PubMed/NCBI
29	Tang Z, Ji L, Han M, Xie J, Zhong F, Zhang X, Su Q, Yang Z, Liu Z, Gao H and Jiang G: Pyroptosis is involved in the inhibitory effect of FL118 on growth and metastasis in colorectal cancer. Life Sci. 257:1180652020. View Article : Google Scholar
30	Narayanankutty A: PI3K/Akt/mTOR pathway as a therapeutic target for colorectal cancer: A review of preclinical and clinical evidence. Curr Drug Targets. 20:1217–1226. 2019. View Article : Google Scholar : PubMed/NCBI
31	Duan S, Huang W, Liu X, Liu X, Chen N, Xu Q, Hu Y, Song W and Zhou J: IMPDH2 promotes colorectal cancer progression through activation of the PI3K/AKT/mTOR and PI3K/AKT/FOXO1 signaling pathways. J Exp Clin Cancer Res. 37:3042018. View Article : Google Scholar : PubMed/NCBI
32	Liu W, Wang S, Sun Q, Yang Z, Liu M and Tang H: DCLK1 promotes epithelial-mesenchymal transition via the PI3K/Akt/NF-κB pathway in colorectal cancer. Int J Cancer. 142:2068–2079. 2018. View Article : Google Scholar : PubMed/NCBI
33	Liu H, Wang J, Tao Y, Li X, Qin J, Bai Z, Chi B, Yan W and Chen X: Curcumol inhibits colorectal cancer proliferation by targeting miR-21 and modulated PTEN/PI3K/Akt pathways. Life Sci. 221:354–361. 2019. View Article : Google Scholar
34	Yang Z, Zhang C, Qi W, Cui Y and Xuan Y: GLI1 promotes cancer stemness through intracellular signaling pathway PI3K/Akt/NFκB in colorectal adenocarcinoma. Exp Cell Res. 373:145–154. 2018. View Article : Google Scholar : PubMed/NCBI
35	Wei R, Xiao Y, Song Y, Yuan H, Luo J and Xu W: FAT4 regulates the EMT and autophagy in colorectal cancer cells in part via the PI3K-AKT signaling axis. J Exp Clin Cancer Res. 38:1122019. View Article : Google Scholar : PubMed/NCBI